Asher Bio Announces New Preclinical Data Demonstrating Best-in-Class Potential of AB248, Its Lead Cis-Targeted Il-2 Immunotherapy

—Selective targeting of IL-2, a potent immunomodulator, to CD8+ T cells results in enhanced anti-tumor activity across multiple in vivo animal models and an enhanced safety profile —

— IND filing for AB248 on-track for 3Q 2022 —

Excerpt from the Press Release:

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Asher Biotherapeutics, a biotechnology company developing precisely-directed immunotherapies for cancer, autoimmune, and infectious diseases, today announced new preclinical data demonstrating proof of concept for its cis-targeting platform and lead program AB248. AB248 is an engineered intereukin-2 (IL-2) immunotherapy, designed to selectively target CD8+ effector T cells. The data will be presented at the Society for Immunotherapy of Cancer 36^th Annual Meeting (SITC 2021), being held in Washington D.C. and virtually, November 10-14, 2021.

“We are pleased to share two presentations at SITC, providing further evidence that our cis–targeting approach enables us to craft exquisitely selective molecules, which activate only the desired immune cell types. This approach allows us to deliver immune activators to the cell types that drive efficacy, while avoiding other cell types that can lead to increased toxicities or other undesired consequences. These data provide further validation for our platform, which has now generated multiple lead molecules against high value targets and support our efforts to advance a pipeline of immunotherapies to provide better outcomes to patients,” said Andy Yeung, Ph.D., Chief Technology Officer and Founder of Asher Bio.

Click the button below to read the entire Press Release:

Continue Reading The Press Release